Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01748929 |
Recruitment Status :
Completed
First Posted : December 13, 2012
Last Update Posted : August 29, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Intestinal Diseases, Parasitic | Drug: Albendazole Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1010 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth |
Actual Study Start Date : | February 24, 2014 |
Actual Primary Completion Date : | February 13, 2015 |
Actual Study Completion Date : | September 16, 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Albendazole
single dose 400 mg tablet of albendazole
|
Drug: Albendazole |
Placebo Comparator: Placebo
Placebo Manufactured by Hersil Laboratories in Lima, Peru
|
Drug: Placebo |
- Mean (± standard deviation) weight gain (kg) [ Time Frame: Change between birth and six months of age ]
- Infant morbidity [ Time Frame: 1, 6, 12, 24 months following birth ]
- Maternal hemoglobin levels and anemia [ Time Frame: 1, 6, 12, 24 months following birth ]
- Breastfeeding practices [ Time Frame: 1, 6, 12, 24 months following birth ]The prevalence of current, exclusive, predominant and partial breastfeeding will be used to assess breastfeeding practices. In accordance with WHO criteria, infants will be considered as exclusively breastfed if they ingest only breast milk (excluding vitamins and medications); considered as predominantly breastfed if, in addition to breast milk, they also ingest water, juice, teas, vitamins or medications, and considered as partially breastfed if their primary nutrition source is other than breast milk.
- Maternal energy levels [ Time Frame: 1, 6, 12, 24 months following birth ]Maternal energy levels will be measured using an adapted 5-item version of the Fatigue Assessment Scale (FAS) (Michielsen et al. 2004). This scale assesses symptoms of physical and cognitive fatigue.
- Maternal STH infection [ Time Frame: 1 and 6 months following birth ]
- Breast milk quality [ Time Frame: 1 and 6 months following birth ]Mean concentrations of key breast milk quality indicators (i.e. macronutrients, immunological factors, vitamins, and minerals) will be used to assess breast milk quality.
- Breast milk quantity transferred from mother to infant [ Time Frame: 1 and 6 months following birth ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Deliver at Hospital Iquitos
- Plan to reside in Iquitos or neighbouring area for the next 24 months
- Able to communicate in Spanish
Exclusion Criteria:
- Deliver multiples
- Delivery a stillborn or an infant with a serious congenital medical condition
- Transfered to another hospital prior to discharge
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01748929
Peru | |
Asociación Civil Selva Amazónica | |
Iquitos, Peru |
Principal Investigator: | Theresa W Gyorkos, PhD | McGill University Health Centre/Research Institute of the McGill University Health Centre | |
Principal Investigator: | Martin Casapia, MD, MPH | Asociación Civil Selva Amazónica |
Responsible Party: | Dr. Theresa Gyorkos, Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre |
ClinicalTrials.gov Identifier: | NCT01748929 |
Other Study ID Numbers: |
12-198-GEN |
First Posted: | December 13, 2012 Key Record Dates |
Last Update Posted: | August 29, 2017 |
Last Verified: | August 2017 |
Global Health Deworming Postpartum Soil-Transmitted Helminths Pregnant Women |
Parasitic Diseases Intestinal Diseases, Parasitic Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Infections Albendazole Anthelmintics Antiparasitic Agents |
Anti-Infective Agents Anticestodal Agents Antiplatyhelmintic Agents Antiprotozoal Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |